Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
William Andrew Macan, the Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary of Neuronetics , Inc. (NASDAQ:STIM), recently sold 377 shares of the company’s common stock. The shares were sold at an average price of $4.48 each, totaling approximately $1,688. The stock has shown remarkable momentum, with InvestingPro data showing a 236% year-to-date return and an impressive 599% surge over the past six months.
These transactions, dated March 4, 2025, were non-discretionary sales made to satisfy tax withholding obligations upon the vesting of a portion of a restricted stock unit award. Following this sale, Macan holds 526,805 shares directly in the company, which currently maintains a market capitalization of $275.2 million.
The sales were executed in multiple transactions, with the share prices ranging from $4.32 to $4.72. For deeper insights into insider trading patterns and comprehensive financial analysis, InvestingPro subscribers can access detailed reports covering 1,400+ US stocks, including Neuronetics.
In other recent news, Neuronetics reported its fourth-quarter 2024 earnings, with revenue reaching $22.5 million, surpassing expectations of $18.97 million and marking an 11% year-over-year increase. The company’s net loss was $0.33 per share, which was below the forecasted loss of $0.24 per share. Following the earnings announcement, Canaccord Genuity raised its price target for Neuronetics to $8.00 while maintaining a Buy rating, citing the company’s slightly better-than-expected earnings. Neuronetics’ merger with Greenbrook TMS, completed in December 2024, has already started to show benefits, contributing $4.4 million from U.S. clinic operations to the quarterly revenue. Citizens JMP reaffirmed its Market Outperform rating for Neuronetics, highlighting the company’s 2025 revenue growth forecast of 12%-19%, amounting to $145 million to $155 million. The company aims to achieve positive cash flow by the third quarter of 2025 and expects gross margins of approximately 55%. Neuronetics plans to expand its Better Me Provider program and increase the utilization of its systems, including the SPRAVATO treatment at Greenbrook locations. The company also anticipates realizing 90% of the $22 million in projected deal synergies by the end of 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.